Skip to main content
. 2021 Nov 25;12:757038. doi: 10.3389/fneur.2021.757038

Table 4.

COVID-19 and multiple sclerosis awareness.

Participants' gender Male Female
Participants' age (years) ≤55 % or SE >55 % or SE p ≤55 % or SE >55 % or SE p
n of Participants (% of 274) 57 20.80 15 5.47 174 63.50 28 10.22
Level of trust toward sources of COVID and MS-related information (mean, SE)
Treating neurologist 5.51 0.23 5.40 0.48 0.832 5.67 0.11 5.46 0.32 0.508
Sites of scientific organizations 4.72 0.25 4.47 0.52 0.647 5.07 0.13 5.00 0.42 0.877
MS center telephone communicational 3.37 0.27 2.93 0.57 0.469 2.93 0.16 3.82 0.38 0.038
MS center site 4.04 0.27 3.60 0.51 0.456 4.36 0.15 4.50 0.41 0.725
Other sites 3.93 0.23 3.07 0.40 0.080 4.29 0.14 4.29 0.42 0.997
Health professional consultation 4.09 0.27 4.40 0.48 0.595 4.13 0.16 4.61 0.39 0.273
Patients' organizations 4.16 0.28 3.80 0.52 0.553 3.92 0.16 4.75 0.40 0.055
Other PwMS 3.09 0.28 2.80 0.43 0.626 2.76 0.15 3.68 0.44 0.057
Social media 3.53 0.27 2.00 0.34 0.001 3.60 0.16 3.54 0.40 0.883
Type of COVID and MS-related information frequently sought ( n , %)
Risk of SARS-CoV infection for PwMS free from DMTs 35 12.77 9 3.28 0.921 87 31.75 16 5.84 0.483
Risk of SARS-CoV infection for PwMS under DMTs 50 18.25 12 4.38 0.442 162 59.12 18 6.57 <0.001
MS and working conditions during the pandemic 42 15.33 11 4.01 0.978 135 49.27 15 5.47 0.025
MS during the pandemic 55 20.07 15 5.47 0.462 162 59.12 25 9.12 0.765
DMTs for MS during the pandemic 50 18.25 12 4.38 0.442 150 54.74 17 6.20 0.004
Personal experience of PwMS regarding the pandemic 33 12.04 5 1.82 0.090 95 34.67 12 4.38 0.505
Caregiving for PwMS during the pandemic 33 12.04 10 3.65 0.538 95 34.67 13 4.74 0.714
Level of trust regarding the management of COVID-related issues for PwMS (mean, SE)
Treating neurologist 6.25 0.14 5.93 0.30 0.32 6.37 0.07 6.36 0.18 0.935
MS centers 5.60 0.18 4.87 0.39 0.07 5.55 0.10 5.54 0.32 0.954
MS-related scientific organizations 5.37 0.18 4.80 0.43 0.17 5.43 0.10 5.43 0.32 0.991
Patients' organizations 4.74 0.21 3.93 0.38 0.08 4.82 0.12 4.82 0.35 0.999
Other medical practitioners 4.76 0.22 5.00 0.35 0.57 4.65 0.16 4.38 0.41 0.516
Company's doctor (if applicable) 3.79 0.37 3.43 0.65 0.67 3.58 0.26 2.86 0.67 0.394
Employer (if applicable) 3.33 0.39 2.67 0.67 0.49 3.25 0.20 2.29 0.75 0.204
Media 2.86 0.20 3.00 0.46 0.76 2.93 0.12 3.75 0.31 0.014
Public hospitals 5.35 0.18 5.47 0.45 0.79 4.99 0.11 5.64 0.31 0.038
Primary health care facilities 4.49 0.21 4.80 0.37 0.50 4.14 0.13 4.61 0.35 0.181
Private clinical 4.05 0.20 2.80 0.34 0.00 4.02 0.13 3.89 0.31 0.704
Ministry of health 4.84 0.24 5.00 0.43 0.76 4.79 0.13 5.25 0.35 0.189
Health professional organization 4.67 0.22 5.07 0.41 0.40 4.72 0.12 4.96 0.35 0.450
Schools 3.40 0.19 2.60 0.38 0.06 3.09 0.11 3.04 0.30 0.864
Universities 3.95 0.21 3.20 0.39 0.11 3.32 0.12 3.43 0.35 0.730
Kindergartens 3.00 0.21 2.47 0.48 0.27 2.74 0.11 2.21 0.25 0.071
Public transportation 2.53 0.19 2.00 0.26 0.18 2.54 0.11 2.46 0.31 0.800

COVID-19, coronavirus disease of 2019; SARS-CoV-2, Severe Acute Respiratory Syndrome Coronavirus-2; MS, Multiple Sclerosis; PwMS, People with Multiple Sclerosis; DMT, Disease-Modifying Treatment; SE, Standard Error of mean. Bold values indicate p < 0.1.